At the 2019 San Antonio Breast Cancer Symposium (SABCS), multiple abstracts will be presented highlighting the clinical progress of Pfizer’s growing breast cancer portfolio.

**Palbociclib:**

**(Abstract PD10-03) Quality of Life in Patients With Hormone Receptor–positive/Human Epidermal Growth Factor–negative Advanced Breast Cancer Treated With Palbociclib in Real-world Practice Settings.** Rocque G. Friday, December 13. Session Type: Spotlight. Presentation Time: 7:00 a.m. – 9:00 a.m. CST. Location: Stars at Night Ballroom 3&4 – 3rd Level.

**(Abstract P1-19-02) Overall Survival for First-line Palbociclib Plus Letrozole vs Letrozole Alone for HR+/HER2-Metastatic Breast Cancer Patients in US Real-world Clinical Practice.** DeMichele A. Wednesday, December 11. Session Type: Poster. Presentation Time: 5:00 p.m. – 7:00 p.m. CST. Location: Hall 1.

**(Abstract P1-19-16) Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for Hormone Receptor–positive/Human Epidermal Growth Factor Receptor 2–negative Advanced Breast Cancer: An Updated Analysis.** Finn RS. Wednesday, December 11. Session Type: Poster. Presentation Time: 5:00 p.m. – 7:00 p.m. CST. Location: Hall 1.

**(Abstract P1-19-26) Characteristics of MBC Patients Receiving First-line Treatments in the US Real-world Setting in the Era of CDK4/6 Inhibitors.** Brufsky A. Wednesday, December 11. Session Type: Poster. Presentation Time: 5:00 p.m. – 7:00 p.m. CST. Location: Hall 1.

**(Abstract P1-19-35) Trends in Daily Mood, Pain, and Fatigue Among Participants in the MADELINE Study.** Richardson D. Wednesday, December 11. Session Type: Poster. Presentation Time: 5:00 p.m. – 7:00 p.m. CST. Location: Hall 1.

**(Abstract P1-19-41) Relationship Between Depression Status and Daily and Weekly Mood in the MADELINE Study.** Richardson D. Wednesday, December 11. Session Type: Poster. Presentation Time: 5:00 p.m. – 7:00 p.m. CST. Location: Hall 1.

**(Abstract P3-11-25) Real-world Treatment Patterns and Clinical Outcomes Among Women With HR+/HER2-Advanced or Metastatic Breast Cancer Treated in Real-world Settings in Italy and Germany.** De Laurentiis M. Thursday, December 12. Session Type: Poster. Presentation Time: 5:00 p.m. – 7:00 p.m. CST. Location: Hall 1.

**(Abstract P5-14-13) Real-world Dosing and CBC Monitoring in Patients With Metastatic Breast Cancer During Palbociclib Plus Letrozole Therapy.** Kish J. Friday, December 13. Session Type: Poster. Presentation Time: 5:00 p.m. – 7:00 p.m. CST. Location: Hall 1.

**Talazoparib:**

**(Abstract PD10-1) Patient-Reported Outcomes in Patients With HER2- Advanced Breast Cancer and a Germline BRCA1/2 Mutation Receiving Talazoparib vs Physician’s Choice of Chemotherapy: A Focus on EMBRACA ECOG
Performance Status Subgroups. Rugo HS. Friday, December 13. Session Type: Spotlight. Presentation Time: 7:00 a.m. – 9:00 a.m. CST. Location: Stars at Night Ballroom 3&4 – 3rd Level.

(Abstract P1-19-29) An Integrated Safety Analysis of Talazoparib Monotherapy From Five Clinical Trials (Phase 1-3) in Advanced Cancers. Ettl J. Wednesday, December 11. Session Type: Poster. Presentation Time: 5:00 p.m. – 7:00 p.m. CST. Location: Hall 1.

(Abstract P2-15-02) BRCA1/2 Status, Treatment Patterns, and Safety Outcomes in HER2-Advanced Breast Cancer (ABC): Results From the European Component of a Multi-country Real-world Study. Lux MP. Thursday, December 12. Session Type: Poster. Presentation Time: 7:00 a.m. – 9:00 a.m. CST. Location: Hall 1.

(Abstract P2-15-06) BRCA1/2 Status, Treatment Patterns and Safety Outcomes in HER2-Advanced Breast Cancer (ABC): Results From a US Real-world Study. Lux MP. Thursday, December 12. Session Type: Poster. Presentation Time: 7:00 a.m. – 9:00 a.m. CST. Location: Hall 1.

(Abstract P6-08-09) BRCA1/2 Testing in Adult Women With HER2-Advanced Breast Cancer (ABC): Results From a US Real World Study. Lux MP. Saturday, December 14. Session Type: Poster. Presentation Time: 7:00 a.m. – 9:00 a.m. CST. Location: Hall 1.

(Abstract P6-08-10) Physician Practice Settings and BRCA1/2 Testing Rates in HER2-Advanced Breast Cancer (ABC): Results From the European Component of a Multi-country Real-world Study. Lux MP. Saturday, December 14. Session Type: Poster. Presentation Time: 7:00 a.m. – 9:00 a.m. CST. Location: Hall 1.

Avelumab + Talazoparib:

(Abstract P1-19-03) JAVELIN PARP Medley, a Phase 1b/2 Study of Avelumab Plus Talazoparib: Results From Advanced Breast Cancer Cohorts. Yap TA. Wednesday, December 11. Session Type: Poster. Presentation Time: 5:00 p.m. – 7:00 p.m. CST. Location: Hall 1.

Trastuzumab Biosimilar:

(Abstract P1-18-08) Trazimera (a Trastuzumab Biosimilar) in HER2-positive Metastatic Breast Cancer: Long-term Safety and Overall Survival Data. Li RK. Wednesday, December 11. Session Type: Poster. Presentation Time: 5:00 p.m. – 7:00 p.m. CST. Location: Hall 1.

###